logo

For the Inventor, By the Inventor

Thousand Oaks, CA, United States of America

Amgen Inc.


USPTO Granted Patents = 2,069

% Expired Patents = 19.1



Trademarks = 76

Forward Citations = 25,223

Loading Chart...
Loading Chart...

2,414 inventors (with patents filed for the assignee):

goldMedal Ning Chen (56 out of 56 patents)

silverMedal Scott Robert Gibson (55 out of 91 patents)

bronzeMedal Thomas Charles Boone (54 out of 55 patents)

4.  Jennifer Rebecca Allen (49 out of 50 patents)

5.  Mark Henry Norman (46 out of 51 patents)

6.  Patricia Lopez (45 out of 45 patents)

7.  Jonathan B Houze (45 out of 56 patents)

8.  Andrew Stewart Tasker (43 out of 66 patents)

9.  Thomas T Nguyen (41 out of 44 patents)

10.  Qingyian Liu (41 out of 41 patents)

11.  Nobuko Nishimura (40 out of 40 patents)

12.  Matthew R Kaller (40 out of 40 patents)

13.  Julio Cesar Medina (40 out of 73 patents)

14.  Chadwick Terence King (39 out of 59 patents)

15.  Jian Jeffrey Chen (39 out of 63 patents)


Core Competencies:
Drug Delivery Device
Automated Visual Inspection
Cancer Treatment
Antibody Constructs
T Cell Engaging
KRAS G12C Inhibitors
Cell Culture Method
Protein Stability
Biomarkers
Quality Evaluation
Pharmaceutical Composition
Syringe Assembly

2,069 patents:

1. 12746343 - Delivery devices for administering drugs (2026-09-29),
2. 12746334 - Drug delivery device having removable cap (2026-09-29),
3. 12742169 - RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION (2026-09-22),
4. 12741977 - Methylation of Mcl-1 compounds (2026-09-22),
5. 12737927 - Image augmentation techniques for automated visual inspection (2026-09-15),
6. 12737891 - Imaging-based system for monitoring quality of cells in culture (2026-09-15),
7. 12735419 - Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-D]pyrimidine-2,4(1H,3H)-dione (2026-09-15),
8. 12734305 - Drug delivery device assembly and accessory for drug delivery device (2026-09-15),
9. 12729911 - Monitoring vial conditions during a lyophilization process (2026-09-08),
10. 12729229 - ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 (2026-09-08),
11. 12729207 - Heterocyclic spiro compounds and methods of use (2026-09-08),
12. 12728199 - Needle insertion mechanism for drug delivery device (2026-09-08),
13. 12723943 - Apparatuses, systems and methods for vial seal inspection (2026-09-01),
14. 12723248 - RNAi constructs for inhibiting ASGR1 expression and methods of use thereof (2026-09-01),
15. 12723047 - Heterocyclic spiro compounds and methods of use (2026-09-01),
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company specializing in the development and manufacturing of innovative drug delivery devices. The organization focuses on advanced therapeutic solutions, particularly in cancer treatment, utilizing technologies such as antibody constructs and T cell engaging therapies. Amgen is also engaged in enhancing drug delivery through automated visual inspection and optimizing cell culture methods to improve protein stability, contributing significantly to the biopharmaceutical landscape.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Amgen Inc.
2,069 Patents

#1 in Thousand Oaks, CA

#63 in California

#249 in US

#487 in the World

Thousand Oaks, CA (US)
Thousand Oaks, CA, United States of America

Amgen Inc.

Forward Citations = 25,223

2,414 inventors:

goldMedal Ning Chen (56 out of 56 patents)

silverMedal Scott Robert Gibson (55 out of 91 patents)

bronzeMedal Thomas Charles Boone (54 out of 55 patents)

4.  Jennifer Rebecca Allen (49 out of 50 patents)

5.  Mark Henry Norman (46 out of 51 patents)

Please report any incorrect information to [email protected]
Loading…